Macular Degeneration Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have at least one large deposit (called a druse) in the eye that is larger than 125 microns in diameter, caused by age-related macular degeneration (AMD).
• People whose vision in the affected eye falls within a specific range — roughly equivalent to seeing between 6/12 and 6/60 on a standard eye chart (sometimes written as 20/40 to 20/200).

Who may not be able to join:

• People who have any implanted electrical device, such as a deep brain stimulator, cochlear implant, auditory brainstem implant, retinal prosthesis, or a heart pacemaker or defibrillator.
• People who have any metal implant within approximately 20 cm of where the treatment electrode would be placed near the eye, or near the back of the neck where a grounding electrode would be placed.
• People whose diabetes is poorly controlled, specifically where a blood sugar marker called HbA1c is above 10%.
• People who currently use tobacco products, or who have a history of heavy smoking (more than half a pack of cigarettes per day on average) within the past 5 years.
• People who have a known severe allergy to fluorescein dye (a dye used in certain eye tests).
• People who have been diagnosed with severe dry eye, defined as needing artificial tears more than 6 times a day or requiring prescription eye drops such as Restasis, Xiidra, or Cequa.
• People who have a history of seizure disorders, chronic migraines, or cluster headaches.
• People who have diabetic retinopathy (eye damage related to diabetes) in either eye, as confirmed by specialist eye imaging.
• People who have other conditions that can cause deterioration of the back of the eye, such as inherited retinal diseases like Stargardt's disease, Best's disease, or similar conditions.
• People who have the "wet" (exudative) form of AMD in the eye being studied, as confirmed by specialist eye imaging.
• People who have a specific type of advanced AMD damage (geographic atrophy) that affects the central part of the retina, called the fovea.
• People who have previously received injections into the eye for geographic atrophy, such as Syfovre or Izervay.
• People who have had photobiomodulation (light-based) therapy or short-pulse laser treatment within the 12 months before screening.
• People who have glaucoma that requires 3 or more medications or eye drops per day, or who have had a specific glaucoma surgery called a trabeculectomy.
• People who have had any type of eye surgery, except for cataract surgery that was performed at least 3 months before the screening visit.
• People who have had a specific laser eye procedure (YAG laser posterior capsulotomy) less than 1 month before the screening visit.
• People who have cataracts or related eye cloudiness that significantly affects their vision.
• People who have a history of amblyopia (commonly known as "lazy eye").

Important: Always verify eligibility with the trial site directly before applying.